Search clinical trials for: CT1812

Total 17 results

Cognition Therapeutics
National Institute on Aging (NIA)

Completed

Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG

Alzheimer Disease

Netherlands
Cognition Therapeutics
National Institute on Aging (NIA)

Recruiting

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (COG1201)

Dementia With Lewy Bodies

United States
Cognition Therapeutics

Completed

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers (COG0107)

Alzheimer Disease

United States
Cognition Therapeutics

Completed

Ascending Dose Study of CT1812 in Healthy Volunteers

Cognitive Impairment

Australia
Cognition Therapeutics
National Institute on Aging (NIA)

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Mild to Moderate Alzheimer's Disease

United States, Australia, Netherlands, Czechia, Spain
Cognition Therapeutics
National Institute on Aging (NIA)

Completed

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects (COG0108)

Alzheimer Disease

United States
Cognition Therapeutics
National Institute on Aging (NIA)

Completed

Effect of CT1812 Treatment on Brain Synaptic Density

Alzheimer Disease

United States
Cognition Therapeutics
National Institute on Aging (NIA); Alzheimer's Clinical Trials Consortium

Recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Early Alzheimer's Disease

United States
Cognition Therapeutics

Recruiting

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Age-Related Macular Degeneration

United States
Cognition Therapeutics

Completed

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

Alzheimer Disease

United States
Cognition Therapeutics

Completed

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Australia
Zhejiang University
Shanghai Zeke Biotechnology Co.，Ltd

Terminated

NK Cell Therapy for AML

AML

China
CRISPR Therapeutics AG

Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Large B-cell Lymphoma | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

United States
Peking University
CARsgen Therapeutics Co., Ltd.

Recruiting

Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
BioCryst Pharmaceuticals

Completed

Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.

Influenza

United States, Canada
Cognition Therapeutics

Completed

Drug Interaction Study of CT1812 in Healthy Volunteers

Healthy Volunteers

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

United States, Puerto Rico, Canada

Search clinical trials for: CT1812

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations